Bosutinib – Uses, Dosage, Side Effects, Interaction Bosutinib is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in the inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies, and solid tumors. The abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype. Bosutinib is a dual kinase inhibitor of both the BCR-ABL and Src tyrosine kinases and is used in the therapy of Philadelphia chromosome-positive chronic myelogenous leukemia. Bosutinib therapy is associated with transient elevations in serum aminotransferase and bilirubin levels and rare instances of clinically apparent acute liver injury. Bosutinib is an aminoquinoline that is 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-[3-(4-methyl piperazine-1-yl)propoxy]quinoline bearing additional cyano and methoxy substituents at positions 3 and 6 respectively. It has a role as an antineoplastic agent and a tyrosine kinase inhibitor. It is a nitrile, N-methyl piperazine, an aromatic ether, a tertiary amino compound, an aminoquinoline, and a dichlorobenzene. Bosutinib Monohydrate is the monohydrate form of bosutinib, a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in the inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies, and solid tumors. The abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype. Mechanism of Action Bosutinib is a tyrosine kinase inhibitor. Although it is able to inhibit several tyrosine kinases such as Src, Lyn, and Hck, which are members of the Src family of kinases, its primary target is the Bcr-Abl kinase. The Bcr-Abl gene is a chimeric oncogene created from the fusion of the breakpoint-cluster (Bcr) gene and the Abelson (Abl) tyrosine gene. This chromosomal abnormality results in the formation of what is commonly known as the Philadelphia chromosome or Philadelphia translocation. The Bcr-Abl gene expresses a particular kinase that promotes the progression of CML. A decrease in the growth and size of the CML tumor has been observed following the administration of bosutinib. Bosutinib did not inhibit the T315I and V299L mutant cells. Indications Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients. Bosulif is indicated for the treatment of adult patients with newly‑diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib, and dasatinib are not considered appropriate treatment options. Bosutinib is a dual kinase inhibitor of both the BCR-ABL and Src tyrosine kinases and is used in the therapy of Philadelphia chromosome-positive chronic myelogenous leukemia. Bosutinib therapy is associated with transient elevations in serum aminotransferase and bilirubin levels and rare instances of clinically apparent acute liver injury. Myeloid Leukemia, Chronic, Chronic Phase Blast phase Chronic myelocytic leukemia Refractory, accelerated phase Chronic myelogenous leukemia Use in Cancer Bosutinib is approved to treat: Chronic myelogenous leukemia (CML) is Philadelphia chromosome positive. It is used: In adults with newly diagnosed chronic phase CML. This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that bosutinib provides a clinical benefit in these patients. In adults with chronic phase, accelerated phase, or blastic phase CML that cannot be treated with or that did not respond to other treatments. Bosutinib is also being studied in the treatment of other types of cancer. Contraindication are allergic to bosutinib or any ingredients of the medication have a history of irregular heartbeat, particularly long QT syndrome have reduced liver function have untreated low potassium or low magnesium in your blood anemia decreased blood platelets low levels of a type of white blood cell called neutrophils fluid in the covering of the heart or pericardium chronic heart failure escape of fluid into the lungs fluid in the lungs liver problems fluid retention in the legs, feet, arms or hands high amount of bilirubin in the blood excessive diarrhea abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding reactivation of hepatitis B infection chronic kidney disease stage 3A (moderate) chronic kidney disease stage 3B (moderate) chronic kidney disease stage 4 (severe) Child-Pugh class A liver impairment Child-Pugh class B liver impairment Child-Pugh class C liver impairment Dosage Strengths: 100 mg; 500 mg; 400 mg Chronic Myelogenous Leukemia Newly-diagnosed: 400 mg orally once daily Duration of therapy: Until disease progression or patient intolerance Chronic/accelerated/blast phase: 500 mg orally once daily Duration of therapy: Until disease progression or patient intolerance Take this drug with food. If a dose is missed beyond 12 hours, the patient should skip the dose and take the usual prescribed dose on the following day. Renal Dose Adjustments RECOMMENDED STARTING DOSE for newly-diagnosed chronic phase Ph+ CML: Normal renal function: 400 mg orally once a day Moderate renal dysfunction (CrCl 30 to 50 mL/min): 300 mg orally once a day Severe renal dysfunction (CrCl less than 30 mL/min): 200 mg orally once a day RECOMMENDED STARTING DOSE for Chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy: Normal renal function: 500 mg orally once a day Moderate renal dysfunction (CrCl 30 to 50 mL/min): 400 mg orally once a day Severe renal dysfunction (CrCl less than 30 mL/min): 300 mg orally once a day Liver Dose Adjustments RECOMMENDED STARTING DOSE for newly-diagnosed chronic phase Ph+ CML: Normal liver function: 400 mg orally once a day Mild, moderate, or severe liver dysfunction (Child-Pugh A, B, or C): 200 mg orally once a day (There are no clinical data for efficacy at the dose of 200 mg once daily in patients with CML) RECOMMENDED STARTING DOSE for Chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy: Normal liver function: 500 mg orally once a day Mild, moderate, or severe liver dysfunction (Child-Pugh A, B, or C): 200 mg orally once a day (There are no clinical data for efficacy at the dose of 200 mg once daily in patients with CML) Dose Adjustments DOSE ESCALATION: The dose can be escalated by increments of 100 mg once daily to a maximum of 600 mg once daily in patients who did not achieve or maintain a hematologic, cytogenetic, or molecular response and who did not have Grade 3 or higher adverse reactions at the recommended starting dosage. NON-HEMATOLOGIC ADVERSE REACTIONS: Elevated liver transaminases: Liver transaminases greater than 5 times the institutional upper limit of normal (ULN): Withhold therapy until recovery to less than or equal to 2.5 x ULN and resume at 400 mg orally once daily thereafter. If recovery takes longer than 4 weeks, discontinue therapy. Liver transaminases greater than or equal to 3 x ULN concurrently with bilirubin greater than 2 x ULN and alkaline phosphatase less than 2 x ULN (Hy’s law case definition): Discontinue therapy Diarrhea: For NCI CTCAE Grade 3 to 4 diarrhea (an increase of greater than or equal to 7 stools/day over baseline/pretreatment): Withhold therapy until recovery to Grade 1 or less. Treatment may be resumed at 400 mg orally once a day. Other Moderate or Severe Non-Hematologic Adverse Reactions: Withhold therapy until resolved, then consider resuming therapy at a dose reduced by 100 mg orally once a day. If appropriate, consider re-escalating the dose to the starting dose once a day. Doses less than 300 mg/day have been used in patients; however, efficacy has not been established MYELOSUPPRESSION: Absolute neutrophil count (ANC) less than 1000 x 10(6)/L OR platelets less than 50,000 x 10(6)/L: Withhold therapy until ANC is greater than or equal to 1000 x 10(6)/L AND platelets are greater than or equal to 50,000 x 10(6)/L. Resume therapy at the same dose if recovery occurs within 2 weeks. If blood counts remain low for more than 2 weeks, upon recovery, reduce the dose by 100 mg and resume therapy. If cytopenia recurs, reduce the dose by an additional 100 mg upon recovery and resume therapy. Doses less than 300 mg/day have been used in patients; however, efficacy has not been established. Side Effects The Most Common headache loss of appetite tiredness or weakness change in the ability to taste food ringing in the ears nausea vomiting diarrhea sudden stomach area pain unexplained bleeding or bruising blood in urine or stool change in the frequency of urination increase or decrease in the amount of urine dizziness fever, sore throat, chills, or other signs of infection shortness of breath and cough chest pain swelling of the face, hands, ankles, feet, or lower legs sudden weight gain yellowing of the skin and eyes dark or tea-colored urine hives rash itching difficulty breathing or swallowing More Common abnormal heart rhythms (such as fast or slow heart rate, palpitations), fainting, or seizures chest pain dizziness fever generalized pain (back pain, muscle pain) increased blood pressure shortness of breath changed sense of taste cold symptoms (e.g., sore throat, runny nose) decreased appetite diarrhea fatigue flu-like symptoms (sudden lack of energy, fever, cough, sore throat) Rare signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath) signs of bleeding (e.g., bloody nose, blood in urine, coughing blood, bleeding gums, cuts that don’t stop bleeding) signs of breathing problems (e.g., shortness of breath, troubled breathing, wheezing, or tightness in chest, fast or irregular breathing) signs of dehydration (e.g., decreased urine, dry skin, dry and sticky mouth, sleepiness, dizziness, headache, thirst, confusion) signs of fluid build-up around the lungs (e.g., chest pain, cough, hiccups, rapid breathing) signs of infection (symptoms may include fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness) signs of kidney failure (e.g., decreased urine production, swelling, fatigue, abdominal pain) signs of liver problems (e.g., nausea, vomiting, diarrhea, loss of appetite, weight loss, yellowing of the skin or whites of the eyes, dark urine, pale stools) signs of pneumonia (e.g., fever, chills, shortness of breath, cough) swelling of the hands, feet, or face symptoms of fluid build-up around the heart (e.g., fever, fatigue, muscle aches, shortness of breath, nausea, vomiting, diarrhea, fast or pounding heartbeat, light-headedness) symptoms of inflammation of the tissue surrounding the heart (pericarditis; e.g., chest pain, cough, fast or irregular heartbeat, shortness of breath, weakness, or fatigue) symptoms of respiratory failure (e.g., dizziness, trouble breathing, shortness of breath, fast, shallow breathing, wheezing, bluish coloration to the skin and lips from lack of oxygen) symptoms of too little phosphorus in the blood (e.g., muscle weakness, fatigue, bone pain, fractures, numbness, confusion) symptoms of too much potassium in the body (e.g., muscle fatigue, weakness, difficulty moving, abnormal heart rhythms, nausea) signs of a serious allergic reaction (e.g., abdominal cramps, difficulty breathing, nausea and vomiting, or swelling of the face and throat) signs of a severe skin reaction such as blistering, peeling, a rash covering a large area of the body, a rash that spreads quickly, or a rash combined with fever or discomfort signs of bleeding in the stomach (e.g., bloody, black, or tarry stools, spitting up of blood, vomiting blood or material that looks like coffee grounds) Drug Interactions DRUG INTERACTION Abaloparatide The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Bosutinib. Abametapir The serum concentration of Bosutinib can be increased when it is combined with Abametapir. Abatacept The metabolism of Bosutinib can be increased when combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Bosutinib. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Bosutinib. Abrocitinib The serum concentration of Bosutinib can be increased when it is combined with Abrocitinib. Acalabrutinib The metabolism of Bosutinib can be decreased when combined with Acalabrutinib. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Bosutinib. Acetaminophen The metabolism of Bosutinib can be increased when combined with Acetaminophen. Acetazolamide The metabolism of Bosutinib can be decreased when combined with Acetazolamide. Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Bosutinib. Adalimumab The metabolism of Bosutinib can be increased when combined with Adalimumab. Adenovirus The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Bosutinib. Afatinib The serum concentration of Bosutinib can be increased when it is combined with Afatinib. Albendazole The metabolism of Bosutinib can be decreased when combined with Albendazole. Aldesleukin The metabolism of Bosutinib can be decreased when combined with Aldesleukin. Alectinib The metabolism of Alectinib can be decreased when combined with Bosutinib. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Bosutinib. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bosutinib. Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Bosutinib. Allogeneic The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Bosutinib. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Bosutinib. Almasilate Almasilate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Almotriptan The metabolism of Almotriptan can be decreased when combined with Bosutinib. Alpelisib The metabolism of Bosutinib can be increased when combined with Alpelisib. Alprazolam The metabolism of Alprazolam can be decreased when combined with Bosutinib. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Bosutinib. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Bosutinib. Aluminium phosphate Aluminium phosphate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Ambrisentan The serum concentration of Bosutinib can be increased when it is combined with Ambrisentan. Aminoglutethimide The metabolism of Bosutinib can be increased when combined with Aminoglutethimide. Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Bosutinib. Aminophylline The metabolism of Aminophylline can be decreased when combined with Bosutinib. Amiodarone The serum concentration of Bosutinib can be increased when it is combined with Amiodarone. Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Bosutinib. Amobarbital The metabolism of Bosutinib can be increased when combined with Amobarbital. Amodiaquine The metabolism of Amodiaquine can be decreased when combined with Bosutinib. Amprenavir The metabolism of Bosutinib can be decreased when combined with Amprenavir. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Bosutinib. Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Bosutinib. Anakinra The metabolism of Bosutinib can be increased when combined with Anakinra. Anastrozole The metabolism of Anastrozole can be decreased when combined with Bosutinib. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Bosutinib. Anifrolumab The risk or severity of adverse effects can be increased when Bosutinib is combined with Anifrolumab. Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Bosutinib. Anthrax immune The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bosutinib. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Bosutinib. Antilymphocyte The risk or severity of adverse effects can be increased when Bosutinib is combined with Antilymphocyte immunoglobulin (horse). Antipyrine The metabolism of Antipyrine can be decreased when combined with Bosutinib. Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Bosutinib. Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Bosutinib. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bosutinib. Apalutamide The serum concentration of Bosutinib can be decreased when it is combined with Apalutamide. Apixaban The metabolism of Apixaban can be decreased when combined with Bosutinib. Apomorphine The metabolism of Apomorphine can be decreased when combined with Bosutinib. Apremilast The metabolism of Bosutinib can be increased when combined with Apremilast. Aprepitant The metabolism of Bosutinib can be decreased when combined with Aprepitant. Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Bosutinib. Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Bosutinib. Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Bosutinib. Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be decreased when combined with Bosutinib. Armodafinil The metabolism of Bosutinib can be increased when combined with Armodafinil. Arsenic trioxide The serum concentration of Bosutinib can be increased when it is combined with Arsenic trioxide. Articaine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Articaine. Asciminib The serum concentration of Bosutinib can be increased when it is combined with Asciminib. Asenapine Asenapine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Astemizole The metabolism of Bosutinib can be decreased when combined with Astemizole. COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Bosutinib. Asunaprevir The serum concentration of Bosutinib can be increased when it is combined with Asunaprevir. Atazanavir The metabolism of Bosutinib can be decreased when combined with Atazanavir. Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Bosutinib. Avacopan The metabolism of Bosutinib can be decreased when combined with Avacopan. Avanafil The serum concentration of Avanafil can be increased when it is combined with Bosutinib. Avatrombopag The serum concentration of Bosutinib can be increased when it is combined with Avatrombopag. Axitinib The metabolism of Axitinib can be decreased when combined with Bosutinib. Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Bosutinib. Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Bosutinib. Azelastine The metabolism of Azelastine can be decreased when combined with Bosutinib. Azithromycin The metabolism of Bosutinib can be decreased when combined with Azithromycin. Bacillus calmette The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Bosutinib. Bacillus calmette The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Bosutinib. Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Bosutinib. Baricitinib The risk or severity of adverse effects can be increased when Bosutinib is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Bosutinib. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Bosutinib. Beclomethasone dipropionate The metabolism of Bosutinib can be increased when combined with Beclomethasone dipropionate. Belantamab mafodotin The serum concentration of Bosutinib can be increased when it is combined with Belantamab mafodotin. Belatacept The risk or severity of adverse effects can be increased when Bosutinib is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Bosutinib is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Belinostat is combined with Bosutinib. Belumosudil The serum concentration of Bosutinib can be increased when it is combined with Belumosudil. Belzutifan The serum concentration of Bosutinib can be decreased when it is combined with Belzutifan. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Bosutinib. Bendamustine The risk or severity of adverse effects can be increased when Bosutinib is combined with Bendamustine. Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Bosutinib. Benzocaine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Benzocaine. Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Bosutinib. Betamethasone The metabolism of Bosutinib can be increased when combined with Betamethasone. Betamethasone phosphate The metabolism of Bosutinib can be increased when combined with Betamethasone phosphate. Betrixaban The serum concentration of Bosutinib can be increased when it is combined with Betrixaban. Bexarotene The metabolism of Bosutinib can be increased when combined with Bexarotene. Bicalutamide The metabolism of Bosutinib can be decreased when combined with Bicalutamide. Bifonazole The metabolism of Bosutinib can be decreased when combined with Bifonazole. Bimekizumab The metabolism of Bosutinib can be increased when combined with Bimekizumab. Bismuth subnitrate Bismuth subnitrate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Bisoprolol The serum concentration of Bosutinib can be increased when it is combined with Bisoprolol. Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Bosutinib. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Bosutinib. Blinatumomab The risk or severity of adverse effects can be increased when Bosutinib is combined with Blinatumomab. Boceprevir The metabolism of Bosutinib can be decreased when combined with Boceprevir. Bordetella The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Bosutinib. Bortezomib The metabolism of Bortezomib can be decreased when combined with Bosutinib. Bosentan The metabolism of Bosutinib can be increased when combined with Bosentan. Brentuximab vedotin The metabolism of Brentuximab vedotin can be decreased when combined with Bosutinib. Brigatinib The metabolism of Brigatinib can be decreased when combined with Bosutinib. Brodalumab The risk or severity of adverse effects can be increased when Bosutinib is combined with Brodalumab. Budesonide The metabolism of Bosutinib can be increased when combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Bupivacaine. Buprenorphine The metabolism of Bosutinib can be decreased when combined with Buprenorphine. Busulfan The metabolism of Busulfan can be decreased when combined with Bosutinib. Butacaine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Butacaine. Butalbital The metabolism of Bosutinib can be increased when combined with Butalbital. Butamben The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Butamben. Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Bosutinib. Cabergoline The metabolism of Cabergoline can be decreased when combined with Bosutinib. Calcitriol The metabolism of Bosutinib can be increased when combined with Calcitriol. Calcium carbonate Calcium carbonate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Canagliflozin The serum concentration of Bosutinib can be increased when it is combined with Canagliflozin. Canakinumab The metabolism of Bosutinib can be increased when combined with Canakinumab. Candicidin The metabolism of Bosutinib can be decreased when combined with Candicidin. Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Bosutinib. Cannabidiol The metabolism of Bosutinib can be decreased when combined with Cannabidiol. Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Bosutinib. Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Bosutinib. Capmatinib The serum concentration of Bosutinib can be increased when it is combined with Capmatinib. Capsaicin The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Capsaicin. Carbamazepine The metabolism of Bosutinib can be increased when combined with Carbamazepine. Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Bosutinib. Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Bosutinib. Carfilzomib The serum concentration of Bosutinib can be increased when it is combined with Carfilzomib. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Bosutinib. Carvedilol The serum concentration of Bosutinib can be increased when it is combined with Carvedilol. Cefradine The metabolism of Bosutinib can be increased when combined with Cefradine. Celecoxib The metabolism of Celecoxib can be decreased when combined with Bosutinib. Cenobamate The serum concentration of Bosutinib can be decreased when it is combined with Cenobamate. Cephalexin The metabolism of Bosutinib can be decreased when combined with Cephalexin. Ceritinib The metabolism of Bosutinib can be decreased when combined with Ceritinib. Cerivastatin The metabolism of Bosutinib can be increased when combined with Cerivastatin. Certolizumab pegol The metabolism of Bosutinib can be increased when combined with Certolizumab pegol. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Bosutinib. Chloramphenicol The metabolism of Bosutinib can be decreased when combined with Chloramphenicol. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Chloroprocaine. Chloroquine The metabolism of Chloroquine can be decreased when combined with Bosutinib. Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Bosutinib. Chlorpromazine The metabolism of Bosutinib can be increased when combined with Chlorpromazine. Ciclesonide The risk or severity of adverse effects can be increased when Ciclesonide is combined with Bosutinib. Cilostazol The metabolism of Cilostazol can be decreased when combined with Bosutinib. Cimetidine Cimetidine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Cinchocaine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Cinchocaine. Ciprofloxacin The metabolism of Bosutinib can be decreased when combined with Ciprofloxacin. Cisapride The metabolism of Bosutinib can be decreased when combined with Cisapride. Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Bosutinib. Citalopram The metabolism of Bosutinib can be decreased when combined with Citalopram. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Bosutinib. Clarithromycin The serum concentration of Bosutinib can be increased when it is combined with Clarithromycin. Clevidipine The metabolism of Bosutinib can be increased when combined with Clevidipine. Clobazam The metabolism of Bosutinib can be increased when combined with Clobazam. Clobetasol propionate The metabolism of Bosutinib can be increased when combined with Clobetasol propionate. Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Bosutinib. Clofazimine The serum concentration of Bosutinib can be increased when it is combined with Clofazimine. Clofibrate The metabolism of Bosutinib can be increased when combined with Clofibrate. Clomifene The serum concentration of Bosutinib can be increased when it is combined with Clomifene. Clomipramine The metabolism of Clomipramine can be decreased when combined with Bosutinib. Clonidine The metabolism of Clonidine can be decreased when combined with Bosutinib. Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Bosutinib. Clostridium The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bosutinib. Clozapine The risk or severity of neutropenia can be increased when Bosutinib is combined with Clozapine. Cobicistat The serum concentration of Bosutinib can be increased when it is combined with Cobicistat. Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Bosutinib. Cocaine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Cocaine. Colchicine The metabolism of Colchicine can be decreased when combined with Bosutinib. Conivaptan The serum concentration of Bosutinib can be increased when it is combined with Conivaptan. Copanlisib The metabolism of Copanlisib can be decreased when combined with Bosutinib. Corticotropin The metabolism of Bosutinib can be increased when combined with Corticotropin. Cortisone acetate The metabolism of Bosutinib can be increased when combined with Cortisone acetate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bosutinib. Crizotinib The serum concentration of Bosutinib can be increased when it is combined with Crizotinib. Curcumin The serum concentration of Bosutinib can be increased when it is combined with Curcumin. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bosutinib. Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Bosutinib. Cyclophosphamide The metabolism of Bosutinib can be increased when combined with Cyclophosphamide. Cyclosporine Bosutinib may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Bosutinib. Cyproterone acetate The metabolism of Bosutinib can be decreased when combined with Cyproterone acetate. Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Bosutinib. Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Bosutinib. Dabrafenib The serum concentration of Bosutinib can be decreased when it is combined with Dabrafenib. Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Bosutinib. Daclatasvir The serum concentration of Bosutinib can be increased when it is combined with Daclatasvir. Dacomitinib The serum concentration of Bosutinib can be increased when it is combined with Dacomitinib. Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Bosutinib. Dalfopristin The metabolism of Bosutinib can be decreased when combined with Dalfopristin. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Bosutinib. Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Bosutinib. Danazol The metabolism of Bosutinib can be decreased when combined with Danazol. Dapsone The metabolism of Dapsone can be decreased when combined with Bosutinib. Daptomycin The serum concentration of Bosutinib can be increased when it is combined with Daptomycin. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bosutinib. Darolutamide The serum concentration of Bosutinib can be increased when it is combined with Darolutamide. Darunavir The serum concentration of Bosutinib can be increased when it is combined with Darunavir. Dasabuvir The metabolism of Dasabuvir can be decreased when combined with Bosutinib. Dasatinib The metabolism of Bosutinib can be decreased when combined with Dasatinib. Daunorubicin The metabolism of Bosutinib can be decreased when combined with Daunorubicin. Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Bosutinib. Deferasirox The metabolism of Bosutinib can be increased when combined with Deferasirox. Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Bosutinib. Deflazacort The metabolism of Bosutinib can be increased when combined with Deflazacort. Delavirdine The metabolism of Bosutinib can be decreased when combined with Delavirdine. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Bosutinib. Desipramine The metabolism of Bosutinib can be decreased when combined with Desipramine. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Bosutinib. Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Bosutinib. Desvenlafaxine The metabolism of Bosutinib can be decreased when combined with Desvenlafaxine. Deucravacitinib The risk or severity of adverse effects can be increased when Bosutinib is combined with Deucravacitinib. Dexamethasone The metabolism of Bosutinib can be increased when combined with Dexamethasone. Dexamethasone acetate The serum concentration of Bosutinib can be decreased when it is combined with Dexamethasone acetate. Dexibuprofen The metabolism of Dexibuprofen can be decreased when combined with Bosutinib. Dexlansoprazole Dexlansoprazole can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Bosutinib. Dextran The risk or severity of bleeding can be increased when Dextran is combined with Bosutinib. Dextropropoxyphene The metabolism of Bosutinib can be decreased when combined with Dextropropoxyphene. Diclofenac The metabolism of Diclofenac can be decreased when combined with Bosutinib. Dicloxacillin The metabolism of Bosutinib can be increased when combined with Dicloxacillin. Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Bosutinib. Diethylstilbestrol The metabolism of Bosutinib can be decreased when combined with Diethylstilbestrol. Difluocortolone The metabolism of Bosutinib can be increased when combined with Difluocortolone. Digitoxin The metabolism of Digitoxin can be decreased when combined with Bosutinib. Digoxin The serum concentration of Bosutinib can be increased when it is combined with Digoxin. Dihydroergocornine The metabolism of Bosutinib can be decreased when combined with Dihydroergocornine. Dihydroergocristine The metabolism of Bosutinib can be decreased when combined with Dihydroergocristine. Dihydroergotamine The metabolism of Bosutinib can be decreased when combined with Dihydroergotamine. Diltiazem The metabolism of Bosutinib can be decreased when combined with Diltiazem. Dimethyl fumarate The risk or severity of adverse effects can be increased when Bosutinib is combined with Dimethyl fumarate. Dimethyl sulfoxide The metabolism of Bosutinib can be decreased when combined with Dimethyl sulfoxide. Dinutuximab The risk or severity of adverse effects can be increased when Bosutinib is combined with Dinutuximab. Diosmin The serum concentration of Bosutinib can be increased when it is combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Diphenhydramine. Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Bosutinib. Diroximel fumarate The risk or severity of adverse effects can be increased when Bosutinib is combined with Diroximel fumarate. Docetaxel The metabolism of Bosutinib can be decreased when combined with Docetaxel. Dofetilide The metabolism of Dofetilide can be decreased when combined with Bosutinib. Dolutegravir The serum concentration of Bosutinib can be increased when it is combined with Dolutegravir. Domperidone The metabolism of Domperidone can be decreased when combined with Bosutinib. Doxazosin The metabolism of Bosutinib can be decreased when combined with Doxazosin. Doxepin Doxepin can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Doxorubicin The metabolism of Bosutinib can be decreased when combined with Doxorubicin. Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Bosutinib. Dronedarone The serum concentration of Bosutinib can be increased when it is combined with Dronedarone. Drospirenone The metabolism of Bosutinib can be decreased when combined with Drospirenone. Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bosutinib. Duvelisib The metabolism of Bosutinib can be decreased when combined with Duvelisib. Dyclonine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Dyclonine. Ebastine The metabolism of Bosutinib can be decreased when combined with Ebastine. Ebola Zaire The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Bosutinib. Echinacea The metabolism of Bosutinib can be increased when combined with Echinacea. Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Bosutinib. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Bosutinib. Edoxaban The serum concentration of Bosutinib can be increased when it is combined with Edoxaban. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Bosutinib. Efavirenz The metabolism of Bosutinib can be decreased when combined with Efavirenz. Elagolix The serum concentration of Bosutinib can be increased when it is combined with Elagolix. Elbasvir The serum concentration of Bosutinib can be increased when it is combined with Elbasvir. Elexacaftor The metabolism of Bosutinib can be decreased when combined with Elexacaftor. Eliglustat The metabolism of Eliglustat can be decreased when combined with Bosutinib. Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Bosutinib. Elvitegravir The metabolism of Bosutinib can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Bosutinib can be increased when combined with Emapalumab. Enasidenib The serum concentration of Bosutinib can be increased when it is combined with Enasidenib. Enfortumab vedotin The serum concentration of Bosutinib can be increased when it is combined with Enfortumab vedotin. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Bosutinib. Entrectinib The serum concentration of Bosutinib can be increased when it is combined with Entrectinib. Enzalutamide The serum concentration of Bosutinib can be decreased when it is combined with Enzalutamide. Epinastine Epinastine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Epinephrine The metabolism of Bosutinib can be decreased when combined with Epinephrine. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Bosutinib. Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Bosutinib. Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Bosutinib. Erdafitinib The serum concentration of Bosutinib can be increased when it is combined with Erdafitinib. Ergotamine The metabolism of Bosutinib can be decreased when combined with Ergotamine. Eribulin The risk or severity of adverse effects can be increased when Bosutinib is combined with Eribulin. Erlotinib The metabolism of Bosutinib can be decreased when combined with Erlotinib. Ertugliflozin The serum concentration of Bosutinib can be increased when it is combined with Ertugliflozin. Erythromycin The serum concentration of Bosutinib can be increased when it is combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bosutinib. Esomeprazole Esomeprazole can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Estetrol The metabolism of Bosutinib can be decreased when combined with Estetrol. Estradiol The metabolism of Estradiol can be decreased when combined with Bosutinib. Estradiol acetate The metabolism of Bosutinib can be increased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Bosutinib can be increased when combined with Estradiol benzoate. Estradiol cypionate The metabolism of Bosutinib can be increased when combined with Estradiol cypionate. Estradiol dienanthate The metabolism of Bosutinib can be increased when combined with Estradiol dienanthate. Estradiol valerate The metabolism of Bosutinib can be increased when combined with Estradiol valerate. Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Bosutinib. Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Bosutinib. Etanercept The metabolism of Bosutinib can be increased when combined with Etanercept. Ethambutol The metabolism of Bosutinib can be decreased when combined with Ethambutol. Ethanol The metabolism of Bosutinib can be increased when combined with Ethanol. Ethinylestradiol The metabolism of Ethinylestradiol can be decreased when combined with Bosutinib. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Etidocaine. Etoposide The metabolism of Etoposide can be decreased when combined with Bosutinib. Etoricoxib The metabolism of Bosutinib can be decreased when combined with Etoricoxib. Etravirine The metabolism of Bosutinib can be increased when combined with Etravirine. Everolimus The serum concentration of Bosutinib can be increased when it is combined with Everolimus. Famotidine Famotidine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Favipiravir The serum concentration of Bosutinib can be increased when it is combined with Favipiravir. Fedratinib The serum concentration of Bosutinib can be increased when it is combined with Fedratinib. Felbamate The metabolism of Bosutinib can be increased when combined with Felbamate. Fenofibrate The metabolism of Bosutinib can be decreased when combined with Fenofibrate. Fentanyl The metabolism of Fentanyl can be decreased when combined with Bosutinib. Fexinidazole The metabolism of Bosutinib can be decreased when combined with Fexinidazole. Fexofenadine The serum concentration of Bosutinib can be increased when it is combined with Fexofenadine. Filgotinib The serum concentration of Bosutinib can be increased when it is combined with Filgotinib. Finerenone The serum concentration of Finerenone can be increased when it is combined with Bosutinib. Fingolimod Bosutinib may increase the immunosuppressive activities of Fingolimod. Flibanserin The serum concentration of Bosutinib can be increased when it is combined with Flibanserin. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Bosutinib. Flucloxacillin The metabolism of Bosutinib can be increased when combined with Flucloxacillin. Fluconazole The serum concentration of Bosutinib can be increased when it is combined with Fluconazole. Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Bosutinib. Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Bosutinib. Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Bosutinib. Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Bosutinib. Flunisolide The metabolism of Bosutinib can be increased when combined with Flunisolide. Fluocinolone acetonide The metabolism of Bosutinib can be increased when combined with Fluocinolone acetonide. Fluocinonide The metabolism of Bosutinib can be increased when combined with Fluocinonide. Fluocortolone The metabolism of Bosutinib can be increased when combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Bosutinib. Fluorouracil The metabolism of Fluorouracil can be decreased when combined with Bosutinib. Fluoxetine The metabolism of Bosutinib can be decreased when combined with Fluoxetine. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Bosutinib. Fluprednisolone The risk or severity of adverse effects can be increased when Bosutinib is combined with Fluprednisolone. Fluticasone The metabolism of Bosutinib can be increased when combined with Fluticasone. Fluticasone furoate The metabolism of Bosutinib can be increased when combined with Fluticasone furoate. Fluticasone propionate The metabolism of Bosutinib can be decreased when combined with Fluticasone propionate. Fluvastatin The metabolism of Fluvastatin can be decreased when combined with Bosutinib. Fluvoxamine The metabolism of Bosutinib can be decreased when combined with Fluvoxamine. Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Bosutinib. Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Bosutinib. Formestane The metabolism of Bosutinib can be increased when combined with Formestane. Fosamprenavir The metabolism of Bosutinib can be decreased when combined with Fosamprenavir. Fosaprepitant The metabolism of Bosutinib can be increased when combined with Fosaprepitant. Fosnetupitant The metabolism of Bosutinib can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Bosutinib can be increased when combined with Fosphenytoin. Fostamatinib The metabolism of Bosutinib can be decreased when combined with Fostamatinib. Fostemsavir The serum concentration of Bosutinib can be increased when it is combined with Fostemsavir. Fusidic acid The metabolism of Bosutinib can be decreased when combined with Fusidic acid. Futibatinib The serum concentration of Bosutinib can be increased when it is combined with Futibatinib. Gallium nitrate The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Bosutinib. Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Bosutinib. Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bosutinib. Gilteritinib The metabolism of Bosutinib can be decreased when combined with Gilteritinib. Ginkgo biloba The metabolism of Bosutinib can be decreased when combined with Ginkgo biloba. Glasdegib The serum concentration of Bosutinib can be increased when it is combined with Glasdegib. Glatiramer The risk or severity of adverse effects can be increased when Glatiramer is combined with Bosutinib. Glecaprevir The serum concentration of Bosutinib can be increased when it is combined with Glecaprevir. Glyburide The metabolism of Bosutinib can be decreased when combined with Glyburide. Glycerol phenylbutyrate The metabolism of Bosutinib can be increased when combined with Glycerol phenylbutyrate. Golimumab The metabolism of Bosutinib can be increased when combined with Golimumab. Grazoprevir The serum concentration of Bosutinib can be increased when it is combined with Grazoprevir. Griseofulvin The metabolism of Bosutinib can be increased when combined with Griseofulvin. Hydrocortamate The metabolism of Bosutinib can be increased when combined with Hydrocortamate. Hydrocortisone The metabolism of Bosutinib can be increased when combined with Hydrocortisone. Hydrocortisone acetate The metabolism of Bosutinib can be increased when combined with Hydrocortisone acetate. Hydrocortisone butyrate The metabolism of Bosutinib can be increased when combined with Hydrocortisone butyrate. Hydrocortisone succinate The metabolism of Bosutinib can be increased when combined with Hydrocortisone succinate. Hydroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Bosutinib. Hydrotalcite Hydrotalcite can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Hydroxychloroquine The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Bosutinib. Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Bosutinib. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bosutinib. Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Bosutinib. Ibuprofen The metabolism of Ibuprofen can be decreased when combined with Bosutinib. Ketamine The metabolism of Ketamine can be decreased when combined with Bosutinib. Ketazolam The metabolism of Bosutinib can be decreased when combined with Ketazolam. Ketoconazole The serum concentration of Bosutinib can be increased when it is combined with Ketoconazole. Ketorolac The metabolism of Ketorolac can be decreased when combined with Bosutinib. Lacosamide The metabolism of Bosutinib can be decreased when combined with Lacosamide. Lanreotide The metabolism of Bosutinib can be decreased when combined with Lanreotide. Lansoprazole Lansoprazole can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Lapatinib The serum concentration of Bosutinib can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Bosutinib can be increased when it is combined with Larotrectinib. Lasmiditan The serum concentration of Bosutinib can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Bosutinib can be increased when it is combined with Ledipasvir. Lefamulin The serum concentration of Bosutinib can be increased when it is combined with Lefamulin. Leflunomide The risk or severity of adverse effects can be increased when Bosutinib is combined with Leflunomide. Lemborexant The serum concentration of Bosutinib can be increased when it is combined with Lemborexant. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Bosutinib. Lenvatinib The serum concentration of Bosutinib can be increased when it is combined with Lenvatinib. Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Bosutinib. Lesinurad The metabolism of Bosutinib can be increased when combined with Lesinurad. Letermovir The metabolism of Bosutinib can be decreased when combined with Letermovir. Levacetylmethadol The metabolism of Levacetylmethadol can be decreased when combined with Bosutinib. Levamlodipine The serum concentration of Levamlodipine can be increased when it is combined with Bosutinib. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Levobupivacaine. Levoketoconazole The serum concentration of Bosutinib can be increased when it is combined with Levoketoconazole. Levomilnacipran The metabolism of Levomilnacipran can be decreased when combined with Bosutinib. Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Bosutinib. Lidocaine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Lidocaine. Linagliptin The serum concentration of Bosutinib can be increased when it is combined with Linagliptin. Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Bosutinib. Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Bosutinib. Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Bosutinib. Lipegfilgrastim Bosutinib may increase the myelosuppressive activities of Lipegfilgrastim. Lomitapide The serum concentration of Bosutinib can be increased when it is combined with Lomitapide. Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Bosutinib. Lonafarnib The serum concentration of Bosutinib can be increased when it is combined with Lonafarnib. Loncastuximab tesirine The serum concentration of Bosutinib can be increased when it is combined with Loncastuximab tesirine. Loperamide The metabolism of Loperamide can be decreased when combined with Bosutinib. Lopinavir The serum concentration of Bosutinib can be increased when it is combined with Lopinavir. Lorlatinib The serum concentration of Bosutinib can be decreased when it is combined with Lorlatinib. Losartan The metabolism of Bosutinib can be decreased when combined with Losartan. Lovastatin The metabolism of Lovastatin can be decreased when combined with Bosutinib. Loxapine The serum concentration of Bosutinib can be increased when it is combined with Loxapine. Lumacaftor The serum concentration of Bosutinib can be increased when it is combined with Lumacaftor. Lusutrombopag The serum concentration of Bosutinib can be increased when it is combined with Lusutrombopag. Magaldrate Magaldrate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Bosutinib. Magnesium carbonate Magnesium carbonate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium hydroxide Magnesium hydroxide can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium oxide Magnesium oxide can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium silicate Magnesium silicate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium trisilicate Magnesium trisilicate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Manidipine The metabolism of Bosutinib can be decreased when combined with Manidipine. Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Bosutinib. Meprednisone The metabolism of Bosutinib can be increased when combined with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Bosutinib. Mestranol The metabolism of Mestranol can be decreased when combined with Bosutinib. Metamizole The risk or severity of myelosuppression can be increased when Metamizole is combined with Bosutinib. Methadone The metabolism of Bosutinib can be decreased when combined with Methadone. Methantheline Methantheline can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Methimazole The metabolism of Bosutinib can be decreased when combined with Methimazole. Methotrexate The metabolism of Methotrexate can be decreased when combined with Bosutinib. Methoxy polyethylene The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bosutinib. Methylene blue The serum concentration of Bosutinib can be increased when it is combined with Methylene blue. Methylergometrine The metabolism of Bosutinib can be decreased when combined with Methylergometrine. Methylphenobarbital The metabolism of Bosutinib can be increased when combined with Methylphenobarbital. Methylprednisolone The metabolism of Bosutinib can be increased when combined with Methylprednisolone. Methylprednisone The metabolism of Bosutinib can be decreased when combined with Methylprednisone. Methysergide The metabolism of Bosutinib can be decreased when combined with Methysergide. Metreleptin The metabolism of Bosutinib can be increased when combined with Metreleptin. Metronidazole The metabolism of Bosutinib can be decreased when combined with Metronidazole. Metyrapone The metabolism of Bosutinib can be increased when combined with Metyrapone. Miconazole The metabolism of Bosutinib can be decreased when combined with Miconazole. Midazolam The serum concentration of Midazolam can be increased when it is combined with Bosutinib. Midostaurin The metabolism of Bosutinib can be decreased when combined with Midostaurin. Mifepristone The serum concentration of Bosutinib can be increased when it is combined with Mifepristone. Milnacipran The metabolism of Bosutinib can be decreased when combined with Milnacipran. Miocamycin The metabolism of Bosutinib can be decreased when combined with Miocamycin. Mirabegron The serum concentration of Bosutinib can be increased when it is combined with Mirabegron. Mirtazapine The metabolism of Bosutinib can be decreased when combined with Mirtazapine. Mitapivat The serum concentration of Bosutinib can be increased when it is combined with Mitapivat. Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Bosutinib. Mitotane The metabolism of Bosutinib can be increased when combined with Mitotane. Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Bosutinib. Mobocertinib The serum concentration of Bosutinib can be decreased when it is combined with Mobocertinib. Modafinil The metabolism of Bosutinib can be increased when combined with Modafinil. Moderna COVID-19 Vaccine The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Bosutinib. Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Bosutinib. Mometasone furoate The metabolism of Bosutinib can be increased when combined with Mometasone furoate. Monomethyl fumarate The risk or severity of adverse effects can be increased when Bosutinib is combined with Monomethyl fumarate. Montelukast The metabolism of Montelukast can be decreased when combined with Bosutinib. Morphine The metabolism of Morphine can be decreased when combined with Bosutinib. Mosunetuzumab The metabolism of Bosutinib can be decreased when combined with Mosunetuzumab. Mumps virus strain The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Bosutinib. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Bosutinib. Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Bosutinib. Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bosutinib. Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Bosutinib. Nafcillin The metabolism of Bosutinib can be increased when combined with Nafcillin. Naloxone The metabolism of Bosutinib can be decreased when combined with Naloxone. Naproxen The metabolism of Naproxen can be decreased when combined with Bosutinib. Natalizumab The risk or severity of adverse effects can be increased when Bosutinib is combined with Natalizumab. Nefazodone The metabolism of Bosutinib can be decreased when combined with Nefazodone. Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Bosutinib. Nelfinavir The metabolism of Bosutinib can be decreased when combined with Nelfinavir. Neratinib The serum concentration of Bosutinib can be increased when it is combined with Neratinib. Netupitant The serum concentration of Bosutinib can be increased when it is combined with Netupitant. Niacin The metabolism of Bosutinib can be decreased when combined with Niacin. Nicardipine The metabolism of Bosutinib can be decreased when combined with Nicardipine. Nilotinib The serum concentration of Bosutinib can be increased when it is combined with Nilotinib. Nilvadipine The metabolism of Bosutinib can be decreased when combined with Nilvadipine. Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Bosutinib. Nintedanib The metabolism of Bosutinib can be decreased when combined with Nintedanib. Nizatidine Nizatidine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Norethisterone The metabolism of Bosutinib can be decreased when combined with Norethisterone. Norgestimate The serum concentration of Bosutinib can be increased when it is combined with Norgestimate. Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Bosutinib. Noscapine The metabolism of Bosutinib can be decreased when combined with Noscapine. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Bosutinib. Obinutuzumab The risk or severity of adverse effects can be increased when Bosutinib is combined with Obinutuzumab. Ocrelizumab The risk or severity of adverse effects can be increased when Bosutinib is combined with Ocrelizumab. Octreotide The serum concentration of Bosutinib can be increased when it is combined with Octreotide. Ofatumumab The risk or severity of adverse effects can be increased when Bosutinib is combined with Ofatumumab. Olanzapine Olanzapine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Olaparib The metabolism of Bosutinib can be decreased when combined with Olaparib. Olodaterol The metabolism of Olodaterol can be decreased when combined with Bosutinib. Omadacycline The serum concentration of Bosutinib can be increased when it is combined with Omadacycline. Ombitasvir The metabolism of Ombitasvir can be decreased when combined with Bosutinib. Omeprazole Omeprazole can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Oritavancin The metabolism of Bosutinib can be increased when combined with Oritavancin. Orphenadrine The metabolism of Bosutinib can be decreased when combined with Orphenadrine. Osilodrostat The metabolism of Bosutinib can be decreased when combined with Osilodrostat. Osimertinib The metabolism of Osimertinib can be decreased when combined with Bosutinib. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bosutinib. Oxcarbazepine The metabolism of Bosutinib can be increased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Oxybuprocaine. Oxybutynin The metabolism of Bosutinib can be decreased when combined with Oxybutynin. Ozanimod The risk or severity of adverse effects can be increased when Bosutinib is combined with Ozanimod. Paclitaxel The metabolism of Bosutinib can be increased when combined with Paclitaxel. Pacritinib The serum concentration of Bosutinib can be increased when it is combined with Pacritinib. Palbociclib The serum concentration of Bosutinib can be increased when it is combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Bosutinib. Paliperidone The serum concentration of Bosutinib can be increased when it is combined with Paliperidone. Panobinostat The metabolism of Panobinostat can be decreased when combined with Bosutinib. Pantoprazole Pantoprazole can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Paramethadione The metabolism of Paramethadione can be decreased when combined with Bosutinib. Parathyroid hormone The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Bosutinib. Paritaprevir The serum concentration of Bosutinib can be increased when it is combined with Paritaprevir. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Bosutinib. Pasireotide The metabolism of Bosutinib can be decreased when combined with Pasireotide. Pazopanib The metabolism of Bosutinib can be decreased when combined with Pazopanib. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bosutinib. Pegcetacoplan The risk or severity of adverse effects can be increased when Bosutinib is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Bosutinib. Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bosutinib. Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Bosutinib. Peginterferon beta-1a The risk or severity of adverse effects can be increased when Bosutinib is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Bosutinib. Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Bosutinib. Pentobarbital The metabolism of Bosutinib can be increased when combined with Pentobarbital. Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Bosutinib. Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Bosutinib. Pentoxifylline The risk or severity of bleeding can be increased when Pentoxifylline is combined with Bosutinib. Perampanel The metabolism of Bosutinib can be increased when combined with Perampanel. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Bosutinib. Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Bosutinib. Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Bosutinib. Phenobarbital The metabolism of Bosutinib can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Phenol. Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Bosutinib. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bosutinib. Phenylbutazone The metabolism of Bosutinib can be increased when combined with Phenylbutazone. Phenytoin The metabolism of Bosutinib can be increased when combined with Phenytoin. Pibrentasvir The serum concentration of Bosutinib can be increased when it is combined with Pibrentasvir. Pimavanserin The metabolism of Bosutinib can be decreased when combined with Pimavanserin. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bosutinib. Pimozide The metabolism of Pimozide can be decreased when combined with Bosutinib. Pioglitazone The metabolism of Pioglitazone can be decreased when combined with Bosutinib. Piperaquine The metabolism of Bosutinib can be decreased when combined with Piperaquine. Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Bosutinib. Piroxicam The metabolism of Piroxicam can be decreased when combined with Bosutinib. Pitavastatin The metabolism of Pitavastatin can be decreased when combined with Bosutinib. Pitolisant The serum concentration of Bosutinib can be decreased when it is combined with Pitolisant. Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Bosutinib. Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Bosutinib. Ponatinib The serum concentration of Bosutinib can be increased when it is combined with Ponatinib. Ponesimod The risk or severity of adverse effects can be increased when Bosutinib is combined with Ponesimod. Posaconazole The metabolism of Bosutinib can be decreased when combined with Posaconazole. Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Bosutinib. Potassium perchlorate The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Bosutinib. Pralatrexate The risk or severity of adverse effects can be increased when Bosutinib is combined with Pralatrexate. Pralsetinib The serum concentration of Bosutinib can be increased when it is combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Pramocaine. Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Bosutinib. Pravastatin The serum concentration of Bosutinib can be increased when it is combined with Pravastatin. Prednisolone The metabolism of Bosutinib can be increased when combined with Prednisolone. Prednisolone acetate The metabolism of Bosutinib can be increased when combined with Prednisolone acetate. Prednisolone phosphate The serum concentration of Bosutinib can be decreased when it is combined with Prednisolone phosphate. Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Bosutinib. Prednisone acetate The metabolism of Bosutinib can be increased when combined with Prednisone acetate. Pretomanid The metabolism of Bosutinib can be decreased when combined with Pretomanid. Prilocaine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Prilocaine. Primaquine The metabolism of Bosutinib can be decreased when combined with Primaquine. Primidone The metabolism of Bosutinib can be increased when combined with Primidone. Probenecid The metabolism of Bosutinib can be increased when combined with Probenecid. Procaine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Procaine. Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Bosutinib. Promethazine Promethazine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Propafenone The serum concentration of Bosutinib can be increased when it is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Proparacaine. Propofol The metabolism of Bosutinib can be decreased when combined with Propofol. Propoxycaine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Propoxycaine. Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Bosutinib. Protein C The risk or severity of bleeding can be increased when Protein C is combined with Bosutinib. Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Bosutinib. Protirelin The therapeutic efficacy of Protirelin can be decreased when used in combination with Bosutinib. Prucalopride The metabolism of Prucalopride can be decreased when combined with Bosutinib. Quinidine The serum concentration of Bosutinib can be increased when it is combined with Quinidine. Quinine The serum concentration of Bosutinib can be increased when it is combined with Quinine. Quinupristin The metabolism of Bosutinib can be decreased when combined with Quinupristin. Rabeprazole Rabeprazole can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Rabies immune The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Bosutinib. Rabies antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bosutinib. Rabies virus B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Bosutinib. Raloxifene The metabolism of Bosutinib can be decreased when combined with Raloxifene. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Bosutinib. Ranitidine Ranitidine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Ranolazine The serum concentration of Bosutinib can be increased when it is combined with Ranolazine. Ravulizumab The risk or severity of adverse effects can be increased when Bosutinib is combined with Ravulizumab. Regorafenib The serum concentration of Bosutinib can be increased when it is combined with Regorafenib. Relugolix The serum concentration of Bosutinib can be increased when it is combined with Relugolix. Remdesivir The metabolism of Bosutinib can be decreased when combined with Remdesivir. Repaglinide The metabolism of Repaglinide can be decreased when combined with Bosutinib. Reserpine The serum concentration of Bosutinib can be increased when it is combined with Reserpine. Retapamulin The metabolism of Retapamulin can be decreased when combined with Bosutinib. Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Bosutinib. Revefenacin The serum concentration of Bosutinib can be increased when it is combined with Revefenacin. Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Bosutinib. Ribociclib The metabolism of Bosutinib can be decreased when combined with Ribociclib. Rifampicin The serum concentration of Bosutinib can be decreased when it is combined with Rifampicin. Rifamycin The serum concentration of Bosutinib can be increased when it is combined with Rifamycin. Rifapentine The metabolism of Bosutinib can be increased when combined with Rifapentine. Rilonacept The metabolism of Bosutinib can be increased when combined with Rilonacept. Rilpivirine The metabolism of Bosutinib can be decreased when combined with Rilpivirine. Rimegepant The serum concentration of Bosutinib can be increased when it is combined with Rimegepant. Riociguat The metabolism of Riociguat can be decreased when combined with Bosutinib. Ripretinib The serum concentration of Bosutinib can be increased when it is combined with Ripretinib. Risankizumab The risk or severity of adverse effects can be increased when Bosutinib is combined with Risankizumab. Ritonavir The serum concentration of Bosutinib can be increased when it is combined with Ritonavir. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Bosutinib. Rivaroxaban The serum concentration of Bosutinib can be increased when it is combined with Rivaroxaban. Rofecoxib The metabolism of Bosutinib can be increased when combined with Rofecoxib. Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Bosutinib. Rolapitant The serum concentration of Bosutinib can be increased when it is combined with Rolapitant. Romidepsin The metabolism of Romidepsin can be decreased when combined with Bosutinib. Ropeginterferon alfa-2b The risk or severity of adverse effects can be increased when Bosutinib is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Ropivacaine. Rosiglitazone The metabolism of Rosiglitazone can be decreased when combined with Bosutinib. Rosuvastatin The metabolism of Bosutinib can be decreased when combined with Rosuvastatin. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Bosutinib. Roxadustat The metabolism of Roxadustat can be decreased when combined with Bosutinib. Roxithromycin The metabolism of Bosutinib can be decreased when combined with Roxithromycin. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Bosutinib. Rucaparib The metabolism of Bosutinib can be decreased when combined with Rucaparib. Rufinamide The metabolism of Bosutinib can be increased when combined with Rufinamide. Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Bosutinib. Salmon calcitonin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Bosutinib. Sapropterin The serum concentration of Bosutinib can be increased when it is combined with Sapropterin. Saquinavir The serum concentration of Bosutinib can be increased when it is combined with Saquinavir. Sarecycline The serum concentration of Bosutinib can be increased when it is combined with Sarecycline. Sarilumab The metabolism of Bosutinib can be increased when combined with Sarilumab. Satralizumab The serum concentration of Bosutinib can be decreased when it is combined with Satralizumab. Secobarbital The metabolism of Bosutinib can be increased when combined with Secobarbital. Secukinumab The metabolism of Bosutinib can be increased when combined with Secukinumab. Selegiline The metabolism of Selegiline can be decreased when combined with Bosutinib. Selexipag The metabolism of Selexipag can be decreased when combined with Bosutinib. Selumetinib The metabolism of Selumetinib can be decreased when combined with Bosutinib. Sildenafil The serum concentration of Bosutinib can be increased when it is combined with Sildenafil. Silodosin The serum concentration of Bosutinib can be increased when it is combined with Silodosin. Siltuximab The metabolism of Bosutinib can be increased when combined with Siltuximab. Simeprevir The serum concentration of Bosutinib can be increased when it is combined with Simeprevir. Simvastatin The serum concentration of Bosutinib can be increased when it is combined with Simvastatin. Siponimod The metabolism of Siponimod can be decreased when combined with Bosutinib. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Bosutinib. Sirolimus The metabolism of Sirolimus can be decreased when combined with Bosutinib. Sitagliptin The metabolism of Sitagliptin can be decreased when combined with Bosutinib. Sitaxentan The metabolism of Bosutinib can be decreased when combined with Sitaxentan. Smallpox (Vaccinia) Vaccine, Live The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Bosutinib. Sodium bicarbonate Sodium bicarbonate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Bosutinib. Sodium zirconium cyclosilicate Sodium zirconium cyclosilicate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Sofosbuvir The serum concentration of Bosutinib can be increased when it is combined with Sofosbuvir. Somatostatin The metabolism of Bosutinib can be decreased when combined with Somatostatin. Somatrogon The metabolism of Bosutinib can be increased when combined with Somatrogon. Sonidegib The metabolism of Sonidegib can be decreased when combined with Bosutinib. Sorafenib The serum concentration of Bosutinib can be increased when it is combined with Sorafenib. Sotagliflozin The serum concentration of Bosutinib can be increased when it is combined with Sotagliflozin. Sotorasib The serum concentration of Bosutinib can be decreased when it is combined with Sotorasib. Spesolimab The risk or severity of adverse effects can be increased when Bosutinib is combined with Spesolimab. St. John’s Wort The serum concentration of Bosutinib can be decreased when it is combined with St. John’s Wort. Stiripentol The metabolism of Bosutinib can be decreased when combined with Stiripentol. Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Bosutinib. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Bosutinib. Sulfadiazine The metabolism of Sulfadiazine can be decreased when combined with Bosutinib. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Bosutinib. Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Bosutinib. Sulfinpyrazone The metabolism of Bosutinib can be increased when combined with Sulfinpyrazone. Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Bosutinib. Sunitinib The metabolism of Sunitinib can be decreased when combined with Bosutinib. Suvorexant The serum concentration of Bosutinib can be increased when it is combined with Suvorexant. Tacrolimus The serum concentration of Bosutinib can be increased when it is combined with Tacrolimus. Talazoparib The serum concentration of Bosutinib can be increased when it is combined with Talazoparib. Tamoxifen The serum concentration of Bosutinib can be increased when it is combined with Tamoxifen. Tasimelteon The metabolism of Bosutinib can be decreased when combined with Tasimelteon. Tazarotene The metabolism of Tazarotene can be decreased when combined with Bosutinib. Tazemetostat The metabolism of Bosutinib can be decreased when combined with Tazemetostat. Technetium Tc-99m sestamibi The serum concentration of Bosutinib can be increased when it is combined with Technetium Tc-99m sestamibi. Tecovirimat The metabolism of Bosutinib can be increased when combined with Tecovirimat. Tedizolid phosphate The risk or severity of myelosuppression can be increased when Bosutinib is combined with Tedizolid phosphate. Tegafur The metabolism of Tegafur can be decreased when combined with Bosutinib. Tegaserod The serum concentration of Bosutinib can be increased when it is combined with Tegaserod. Telaprevir The serum concentration of Bosutinib can be increased when it is combined with Telaprevir. Telithromycin The metabolism of Bosutinib can be decreased when combined with Telithromycin. Telotristat ethyl The serum concentration of Bosutinib can be decreased when it is combined with Telotristat ethyl. Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Bosutinib. Temsirolimus The serum concentration of Bosutinib can be increased when it is combined with Temsirolimus. Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Bosutinib. Teniposide The metabolism of Bosutinib can be decreased when combined with Teniposide. Tenofovir alafenamide The metabolism of Bosutinib can be decreased when combined with Tenofovir alafenamide. Tenofovir disoproxil The serum concentration of Bosutinib can be increased when it is combined with Tenofovir disoproxil. Tepotinib The serum concentration of Bosutinib can be increased when it is combined with Tepotinib. Teprotumumab The risk or severity of adverse effects can be increased when Teprotumumab is combined with Bosutinib. Terbinafine The metabolism of Bosutinib can be increased when combined with Terbinafine. Terfenadine The metabolism of Bosutinib can be decreased when combined with Terfenadine. Teriflunomide The risk or severity of adverse effects can be increased when Bosutinib is combined with Teriflunomide. Teriparatide The therapeutic efficacy of Teriparatide can be decreased when used in combination with Bosutinib. Testosterone The metabolism of Bosutinib can be increased when combined with Testosterone. Testosterone cypionate The metabolism of Testosterone cypionate can be decreased when combined with Bosutinib. Pregnancy and Lactation US FDA pregnancy category: Not assigned Pregnancy This medication should not be taken during pregnancy. Bosutinib may cause severe harm to a developing baby if it is taken by the mother while she is pregnant. Female partners of men taking this medication should not become pregnant. Both women and men must use a reliable method of birth control (e.g., condoms, birth control pill) during treatment and for at least 4 weeks after treatment is finished. If you become pregnant while taking this medication, contact your doctor immediately. Lactation No information is available on the clinical use of bosutinib during breastfeeding. Because bosutinib is 96% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 22 hours and it might accumulate in the infant. National Comprehensive Cancer Network guidelines recommend avoiding breastfeeding during bosutinib therapy and the manufacturer recommends withholding breastfeeding until 2 weeks following the last dose. How should this medicine be used? Bosutinib comes as a tablet to take by mouth. It is usually taken with food once a day. Take bosutinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take bosutinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Swallow the tablets whole; do not split, chew, or crush them. If any of the tablets are broken or crushed, do not touch them with your bare hands. Your doctor may temporarily or permanently stop your treatment or adjust your dose of bosutinib depending on your response to treatment and any side effects that you experience. Talk to your doctor about how you are feeling during your treatment. Continue to take bosutinib even if you feel well. Do not stop taking bosutinib without talking to your doctor. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. What special precautions should I follow? Before taking bosutinib, tell your doctor and pharmacist if you are allergic to bosutinib or any of the ingredients in bosutinib tablets. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: certain antifungals such as ketoconazole and itraconazole (Sporanox); aprepitant (Emend); certain medications used to treat human immunodeficiency virus (HIV) such as indinavir (Crixivan), nelfinavir (Viracept), ritonavir (Norvir), and saquinavir (Invirase); medications to reduce stomach acid (proton-pump inhibitors) such as esomeprazole (Nexium), lansoprazole (Prevacid), omeprazole (Prilosec), pantoprazole (Protonix), and rabeprazole (AcipHex); diltiazem (Cardizem, Cartia, Tiazac); erythromycin (E.E.S., E-Mycin, Erythrocin); nefazodone; rifabutin (Mycobutin); and rifampin (Rifadin, Rimactane in Rifamate, in Rifater). Many other medications may also interact with bosutinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. if you are taking antacids, such as aluminum hydroxide/magnesium hydroxide (Maalox), calcium carbonate (Tums) or calcium carbonate and magnesium (Rolaids), or medications to reduce stomach acids, such as cimetidine (Tagamet), famotidine (Pepcid), or ranitidine (Zantac), take them 2 hours before or 2 hours after you take bosutinib. tell your doctor what herbal products you are taking, especially St. John’s wort. tell your doctor if you have or have ever had high blood pressure, diabetes, or kidney, liver, or heart disease. tell your doctor if you are pregnant or plan to become pregnant. You will need to take a pregnancy test before you start treatment and you should not become pregnant while you are taking bosutinib. You should use an effective form of birth control during treatment with bosutinib and for 2 weeks after your final dose. Talk to your doctor about birth control methods that will work for you. If you become pregnant while taking bosutinib, call your doctor. Bosutinib may harm the fetus. tell your doctor if you are breastfeeding. You should not breastfeed while you are taking bosutinib and for 2 weeks after your last dose. you should know that this medication may decrease fertility in men and women. Talk to your doctor about the risks of taking bosutinib. References https://pubchem.ncbi.nlm.nih.gov/compound/Bosutinib https://pubchem.ncbi.nlm.nih.gov/compound/Bosutinib-monohydrate https://www.cancer.gov/about-cancer/treatment/drugs/bosutinib https://go.drugbank.com/drugs/DB06616 https://www.webmd.com/drugs/2/drug-162353/bosutinib-oral/details/list-contraindications https://medlineplus.gov/druginfo/meds/a613005.html https://www.drugs.com/mtm/bosutinib.html https://www.medbroadcast.com/drug/getdrug/bosulif ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL288441/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp https://ctdbase.org/detail.go?type=chem&acc=C471992 Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads https://www.dgidb.org/drugs/BOSUTINIB DrugBank https://www.drugbank.ca/legal/terms_of_use Bosutinib https://www.drugbank.ca/drugs/DB06616 IUPHAR/BPS Guide to PHARMACOLOGY https://www.guidetopharmacology.org/about.jsp#license https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5710 Guide to Pharmacology Target Classification https://www.guidetopharmacology.org/targets.jsp Therapeutic Target Database (TTD) Bosutinib http://idrblab.net/ttd/data/drug/details/D0OB0F CAS Common Chemistry LICENSE The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated. https://creativecommons.org/licenses/by-nc/4.0/ Bosutinib https://commonchemistry.cas.org/detail?cas_rn=380843-75-4 ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Bosutinib [USAN:INN] https://chem.nlm.nih.gov/chemidplus/sid/0380843754 ChemIDplus Chemical Information Classification https://chem.nlm.nih.gov/chemidplus/ EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile https://comptox.epa.gov/dashboard/DTXSID10861568 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile https://echa.europa.eu/substance-information/-/substanceinfo/100.149.122 FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking BOSUTINIB https://gsrs.ncats.nih.gov/ginas/app/beta/substances/5018V4AEZ0 Human Metabolome Database (HMDB) http://www.hmdb.ca/citing Bosutinib http://www.hmdb.ca/metabolites/HMDB0240205 HMDB0240205_msms_450568 https://hmdb.ca/metabolites/HMDB0240205#spectra ChEBI Bosutinib http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:39112 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking BOSUTINIB https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm FDA Pharmacological Classification https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Bosutinib https://www.ncbi.nlm.nih.gov/books/n/livertox/Bosutinib/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C60809 NCI Thesaurus Tree https://ncit.nci.nih.gov ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ European Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/legal-notice Bosulif (EMEA/H/C/002373) https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif Drugs and Lactation Database (LactMed) LICENSE https://www.nlm.nih.gov/copyright.html Bosutinib https://www.ncbi.nlm.nih.gov/books/NBK500844/ EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking BOSUTINIB https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory MassBank of North America (MoNA) LICENSE The content of the MoNA database is licensed under CC BY 4.0. https://mona.fiehnlab.ucdavis.edu/documentation/license Bosutinib (SKI-606) https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=compound.metaData%3Dq%3D%27name%3D%3D%22InChIKey%22%20and%20value%3D%3D%22UBPYILGKFZZVDX-UHFFFAOYSA-N%22%27 NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Bosulif (Bosutinib) https://www.cancer.gov/about-cancer/treatment/drugs/bosutinib NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html https://rxnav.nlm.nih.gov/id/rxnorm/1307619 Protein Data Bank in Europe (PDBe) http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/DB8 PubChem https://pubchem.ncbi.nlm.nih.gov RCSB Protein Data Bank (RCSB PDB) https://www.rcsb.org/pages/policies https://www.rcsb.org/ Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=36062266-807966908 Thieme Chemistry LICENSE The Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated. https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=36062266-807966908 WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ Wikidata LICENSE CCZero https://creativecommons.org/publicdomain/zero/1.0/ Bosutinib https://www.wikidata.org/wiki/Q894611 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html bosutinib https://www.ncbi.nlm.nih.gov/mesh/67471992 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html KEGG LICENSE Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license https://www.kegg.jp/kegg/legal.html Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html NORMAN Suspect List Exchange LICENSE Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0 https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ PATENTSCOPE (WIPO) SID 389929383 https://pubchem.ncbi.nlm.nih.gov/substance/389929383 NCBI https://www.ncbi.nlm.nih.gov/projects/linkout Show More